We are live on ! Find out more
IRWD icon

Ironwood Pharmaceuticals

166 hedge funds and large institutions have $195M invested in Ironwood Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 48 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

56,558% more call options, than puts

Call options by funds: $14.7M | Put options by funds: $26K

86% more capital invested

Capital invested by funds: $105M → $195M (+$90M)

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

7% more funds holding

Funds holding: 155166 (+11)

1.17% more ownership

Funds ownership: 90.35%91.52% (+1.2%)

8% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 48

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
166
Holders Change
+11
Holders Change %
+7.1%
% of All Funds
2.17%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
30
Increased
52
Reduced
48
Closed
18
Calls
$14.7M
Puts
$26K
Net Calls
+$14.7M
Net Calls Change
+$6.65M

IRWD Hedge Fund Activity: Q3 2025 in Review

166 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2025, worth a combined $195M — up 86% from $105M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new IRWD positions and 18 closed out — a net gain of 12 holders — while 52 added to existing stakes and 48 trimmed.

The largest buyer was Bank of America, adding an estimated $8.63M. The largest seller was LSV Asset Management, exiting entirely with an estimated $1.97M sold.

  • 166 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2025, up from 155 in Q2 2025.
  • Funds reported $195M of Ironwood Pharmaceuticals stock for Q3 2025, up 86% quarter-over-quarter.
  • 30 funds opened new Ironwood Pharmaceuticals positions in Q3 2025 and 18 closed out, a net change of +12 holders.
  • The largest Ironwood Pharmaceuticals buyer in Q3 2025 was Bank of America, an estimated $8.63M added.
  • The largest Ironwood Pharmaceuticals seller in Q3 2025 was LSV Asset Management, an estimated $1.97M sold.

Based on aggregated 13F filings for Q3 2025.